Filing Details
- Accession Number:
- 0001562180-24-002771
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-18 17:03:34
- Reporting Period:
- 2024-03-14
- Accepted Time:
- 2024-03-18 17:03:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1590877 | Regenxbio Inc. | RGNX | Biological Products, (No Disgnostic Substances) (2836) | 471851754 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1652824 | T. Kenneth Mills | C/O Regenxbio Inc. 9804 Medical Center Drive Rockville MD 20850 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-14 | 15,000 | $3.76 | 423,035 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-14 | 15,000 | $21.86 | 408,035 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2024-03-14 | 15,000 | $0.00 | 15,000 | $3.76 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 111,354 | 2025-05-19 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades at prices ranging from $21.60 to $22.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The previously granted option, which expires on May 19, 2025, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.
Billionaire Hedge Funds
